Pharmaceuticals

CARGO Therapeutics Inc (NASDAQ: CRGX) Q2 Results

CARGO Therapeutics reported Q2 2024 results with a slight EPS miss and higher-than-expected R&D expenses, while maintaining a strong cash position.

Novo Nordisk Stock Drops on Profit Forecast Revision

Novo Nordisk faces stock drop and competition pressures. Revenue growth vs. profit forecast. Political scrutiny and market strategy in focus.

Eli Lilly's Zepbound Shows Promise in Heart Failure Patients

Eli Lilly's Zepbound & Novo Nordisk's Wegovy show health benefits beyond weight loss, influencing investment strategies in pharmaceutical stocks.

Viking Therapeutics Accelerates Weight Loss Drug Development

Viking Therapeutics' fast-tracked weight loss injection could reshape the market, impacting investors' portfolios and strategies.

Embecta Considers Sale Amid Struggles

Embecta Corp, the top insulin pen needle producer, eyes a sale after a 70% share price drop post-spin-off.

SRPT Stock: Sarepta's Elevidys Gets Green Light for Duchenne Patients

Sarepta Therapeutics Inc (NASDAQ: SRPT) achieves FDA approval for its gene therapy for Duchenne muscular dystrophy in patients aged four and older.

CanaQuest Bolsters Team for CQ-001 Trials

CanaQuest Medical (OTC: CANQF) adds experts to advance CQ-001 through clinical trials for FDA approval in epilepsy.

Sign-Ups For Novo Nordisk's Weight Loss Drug Soar In US

Novo Nordisk's weight loss drug Wegovy experiences booming sign-ups in the US, while facing pricing pressures and emerging competition.

Biogen Tops Q1 Estimates with Alzheimer's Boost

Dive into Biogen's impressive Q1 earnings, featuring an EPS beat and significant LEQEMBI sales growth. Explore what these results mean for the company's 2024 outlook.

Johnson & Johnson (JNJ) Acquires Shockwave Medical (SWAV) for $13.1B

J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the cardiovascular technology sector.

MDGL Stock Soars on FDA Liver Disease Approval

FDA approves first-ever NASH treatment, Rezdiffra, by Madrigal Pharmaceuticals Inc (NASDAQ: MDGL). Breakthrough for millions suffering from liver disease.

Eli Lilly's Zepbound Shows Short-Lived Weight Loss Benefits

Uncover key investment insights in the dynamic obesity drug market. Discover growth, value, and momentum strategies in this evolving healthcare sector.

AbbVie Stock in Focus with Strategic Cerevel Acquisition

AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.

BAYRY Stock: Bayer Faces Major Legal and Drug Dev Setbacks

Bayer's legal and pharmaceutical setbacks are something investors should pay attention to. These issues could impact BAYRY stock value and guide investment decisions.

Investors Watch as Novo Nordisk Pours Billions into Obesity Drugs

Novo Nordisk invests $2.3 billion in France to expand its weight-loss drug production, marking a significant move in the pharmaceutical industry.